Canopy Growth Corp. Surges 14.4% in a Day: Could Shares Hit $25 Before Year’s End?

Canopy Growth Corp. (TSX:WEED) is skyrocketing to new highs. Should investors jump on board, or is it too late?

| More on:

Last month, when Canopy Growth Corp. (TSX:WEED) was trading in the $11 range, I wrote an article about how the stock could soar to $20 before the conclusion of 2017. I realized it was an extremely aggressive price target (implying a ~70% return in less than a quarter), and it seemed far-fetched at the time; however, I emphasized in numerous pieces that the likelihood of potential positive developments would heavily outweigh the potential for negative ones.

Many provinces were shedding light on their plans for nationwide legalization, supply deals were being awarded, and I’d stated that such major short-term catalysts would send shares of all Canadian cannabis stocks exponentially higher before legalization day.

Constellation Brands deal could just be the first of many investments by big sin firms

Although I expected a tonne of positive developments to lift cannabis stocks, with Canopy leading the pack, the investment by beer maker Constellation Brands Inc. (NYSE:STZ) for a ~10% stake in Canopy for $245 million came as a very pleasant surprise.

Not only was the deal an incredible vote of confidence from a massive firm, but it opened a huge door for other sin companies that may follow in Constellation’s footsteps to get a piece of the Canadian green rush. This is a gigantic opportunity for the entire cannabis industry, and the development has clearly brought investor euphoria to new highs following the drought that cannabis stocks experienced a few months ago.

During the summer, when cannabis stocks took a slight pullback, I urged investors to be greedy while others were fearful and predicted that cannabis stocks would make up for lost time by the end of the year; this is indeed what has happened, as shares have now more than doubled since my original buy recommendation on all cannabis stocks in late August.

If you haven’t bought shares yet, it may not be too late; however, the easy money has already been made, as it seems most of the potential for positive developments is already baked in to the stocks of all cannabis companies at current levels.

Is it still safe to buy cannabis stocks?

More industry-wide positive developments are certainly possible (supply deals and major investor announcements), but I believe it’ll be the quarterly results that will dictate the direction of cannabis stocks as we move past legalization day.

One of the reasons why Canopy remains my top pick in the cannabis space is because it’s been wheeling and dealing at a faster rate than that of its peers. As more deals are announced, I suspect the stock will continue to rally, even if such deals won’t be accretive to the company’s bottom line until a much later date.

Bottom line

Cannabis stocks still offer growth unlike anything else in the market today. Shares of WEED have more than doubled in fewer than three months thanks to a sequence of very positive developments, including the announcement of a ~three-million-square-foot, B.C.-based capacity-expansion plan, an investment by Constellation Brands, a supply deal win for N.B., and many other deals that the company has in the past few months.

Are there more developments that could drive shares higher?

Definitely.

However, it appears the best ones may have already happened, so if you’re thinking about betting on Canopy or any other cannabis stocks after such an upward spike, be cautious and only invest what you’re willing to lose. The probability of a short-term pullback has been raised significantly, so make sure you’ve got a long-term time horizon, because short-term pain may be in the cards.

My original target of $20 before the year’s end seemed absurd a few months ago, but now that shares are at $19.36, it seems like my original target will need to be raised to $25, as WEED looks poised to break the $20 mark at some point over the next few days.

Stay smart. Stay hungry. Stay Foolish.

Joey Frenette has no position in any stocks mentioned.  

More on Investing

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Investing

The Secrets That TFSA Millionaires Know

The top secrets of TFSA millionaires are out and can serve as a roadmap for the next millionaires.

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Investing

Got $3,000 for a TFSA? 3 Reliable Canadian Stocks for Long-Term Wealth Building

These Canadian stocks have strong fundamentals and solid growth potential, which makes them reliable stocks for building wealth.

Read more »

Investor wonders if it's safe to buy stocks now
Energy Stocks

Canadian Natural Resources: Buy, Sell, or Hold in 2026?

Buy, Sell, or Hold? Ignore the speculative headlines. With a 5.2% yield and 3% production growth, Canadian Natural Resources stock…

Read more »

Income and growth financial chart
Dividend Stocks

A Canadian Dividend Stock Down 9% to Buy Forever

TELUS has been beaten down, but its +9% yield and improving cash flow could make this dip an income opportunity.

Read more »

dividend growth for passive income
Dividend Stocks

Top Canadian Stocks to Buy for Dividend Growth

These less well-known dividend stocks offer amazing potential for generating increasing income for higher-risk investors.

Read more »

man touches brain to show a good idea
Retirement

Here’s the Average TFSA and RRSP at Age 45

Averages can be a wake-up call, and Manulife could be a simple, dividend-paying way to help your TFSA or RRSP…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

2 Stocks That Could Turn $100,000 Into $0 Faster Than You Think

Canopy Growth and Plug Power are two unprofitable stocks that remain high-risk investments for shareholders in 2026.

Read more »

Real estate investment concept
Dividend Stocks

Down 23%, This Dividend Stock is a Major Long-Time Buy

goeasy’s big drop has pushed its valuation and yield into “paid-to-wait” territory, but only if credit holds up.

Read more »